RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the launch of RAHA-100, its proprietary, bench top generator technology designed to streamline the production of on-demand supply of ²¹²Pb (Lead-212) isotope for research and clinical development of targeted Alpha Therapy (TAT) radiopharmaceuticals.
“Overcoming isotope supply limitations is essential to unlocking the full potential of targeted alpha therapy,” said Ebrahim S. Delpassand, M.D., Chief Executive Officer of RadioMedix. “The RAHA-100 generator represents a transformative step in making ²¹²Pb more accessible, enabling researchers to explore novel applications and helping us accelerate the development of TAT radiopharmaceuticals. We believe this technology will democratize availability of ²¹²Pb and play a pivotal role in shaping the next generation of therapies for hard-to-treat cancers, ultimately broadening access to effective treatment options for more patients.”
